Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression

Autor: Elif Karakoc-Aydiner, Dilek Seckin Gencosmanoglu, Burak Tekin, Andac Salman, Nahide Onsun, Emel Bulbul-Baskan, Aylin Cakiroglu, Tulin Ergun, Erkan Alpsoy
Přispěvatelé: Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı., Bülbül, Emel Baskan
Rok vydání: 2016
Předmět:
Male
Pediatric Obesity
Guttate psoriasis
Turkey
Epidemiology
Disease
Overweight
Adolescents
Betamethasone
Severity of Illness Index
Comorbidities
Body Mass Index
Mmanagement
030207 dermatology & venereal diseases
0302 clinical medicine
Turkey (bird)
Prevalence
Corticosteroid
Pustulosis Palmoplantaris
Psoriatic Arthritis
Metabolic Syndrome
Childhood obesity
030212 general & internal medicine
Prospective Studies
Disease course
Child
Children
Metaanalysis
Metabolic syndrome
Multicenter study
Clinical trial
Body mass
Disease Progression
Female
medicine.symptom
Human
medicine.medical_specialty
Adolescent
Kolmogorov smirnov test
Case control study
Major clinical study
Dermatology
Emotional stress
Article
Association
03 medical and health sciences
Psoriatic arthritis
Vitamin D derivative
Psoriasis Area and Severity Index
Internal medicine
Psoriasis
Severity of illness
medicine
Humans
Obesity
Disease exacerbation
Prospective study
Calcipotriol
Disease severity
Disease duration
Psoriasis area and severity index
business.industry
Case-control study
Follow up
medicine.disease
Disease classification
Paediatric psoriasis
Preschool child
Case-Control Studies
Physical therapy
School child
business
Controlled study
Complication
Body mass index
Zdroj: The Australasian journal of dermatology. 58(4)
ISSN: 1440-0960
Popis: Background/Objectives: The current literature suggests there is a possible connection between paediatric psoriasis and obesity. However, there is a paucity of research on the influence of increased adiposity on the severity of paediatric psoriasis and disease progression. We aimed to compare the prevalence of being overweight or obese in paediatric psoriasis patients and controls and assess the potential impact of being overweight/obese on disease severity and progression of disease. Methods: This multicentre prospective case-control study included 289 psoriasis patients (aged < 18 years) treated and followed up by one of the four university hospitals in Turkey. The control group consisted of 151 consecutive age-matched and sex-matched children who lacked a personal or family history of psoriasis. The participants' characteristics, psoriasis-related parametres (e.g., initial subtype, psoriasis area and severity index, presence of psoriatic arthritis) and body mass index were determined. Results: The difference between the prevalence of being overweight/obese among psoriatics (28%) and the control group (19%) was significant (P = 0.024). Being overweight/obese had no significant impact on disease severity and unresponsiveness to topical treatment. Within a median follow-up time of 12 months, 23% of our patients with localised disease at disease onset progressed to generalised disease. The impact of being overweight/obese on disease progression was found to be non-significant; however, disease duration was found to have a significant impact on disease progression (P = 0.026). Conclusions: Although it is not associated with disease severity and course, increased bodyweight may be a health problem for psoriatic children. Schering Plough Corporation AbbVie Merck & Company Johnson & Johnson Johnson & Johnson USA Janssen Biotech Inc Merck & Company
Databáze: OpenAIRE
Externí odkaz: